Emergent BioSolutions (EBS) Change in Receivables (2010 - 2026)

Emergent BioSolutions' Change in Receivables history runs 17 years deep, the most recent figure standing at $38.9 million for Q1 2026.

• On a quarterly basis, Change in Receivables fell 46.93% year-over-year to $38.9 million in Q1 2026; TTM through Mar 2026 was -$59.9 million, a 225.58% decrease from a year earlier, with the FY2025 full-year figure at -$25.5 million, down 204.51% from the prior year.
• Change in Receivables advanced to $38.9 million in Q1 2026 per EBS's latest filing, from -$51.9 million in the prior quarter.
• Across five years, Change in Receivables topped out at $132.4 million in Q2 2023 and bottomed at -$118.5 million in Q2 2025.
• The 5-year median for Change in Receivables is -$4.0 million (2022), against an average of -$3.5 million.
• Biggest YoY gain for Change in Receivables was 3410.0% in 2023; the steepest drop was 569.08% in 2023.
• Year by year, Change in Receivables stood at -$35.6 million in 2022, then fell by 3.65% to -$36.9 million in 2023, then soared by 308.94% to $77.1 million in 2024, then plunged by 167.32% to -$51.9 million in 2025, then soared by 174.95% to $38.9 million in 2026.
• Per Business Quant, the three latest EBS Change in Receivables figures stand at $38.9 million (Q1 2026), -$51.9 million (Q4 2025), and $71.6 million (Q3 2025).